-
Phase 3 Randomized Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Plus ADT Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (KEYNOTE-991)
The purpose of the trial is to determine the safety and efficacy of the pembrolizumab plus enzalutamide plus ADT versus placebo plus enzalutamide plus androgen ...Phase
Interventional
